Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

Advances in Developing CAR-T Cell Therapy for Colorectal Cancer

[Advances of CAR-T cell therapy in treating colorectal cancer]

Recent advances in CAR-T cells therapy for colorectal cancer

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Current progress in CAR-T cell therapy for tumor treatment

CAR-T cell therapy: Advances in digestive system malignant tumors

Monoclonal antibodies and chimeric antigen receptor (CAR) T cells in the treatment of colorectal cancer

Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Current Progress in CAR-T Cell Therapy for Solid Tumors

Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies

CAR-T therapy for gastrointestinal cancers: current status, challenges, and future directions

A long way to the battlefront: CAR T cell therapy against solid cancers.

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Update for Advance CAR-T Therapy in Solid Tumors, Clinical Application in Peritoneal Carcinomatosis From Colorectal Cancer and Future Prospects

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges